RE:RE:RE:RE:RE:RE:Melphalen flufenamide They are burning cash with speed of light, about 300 M SEK q over q and have about one quarter of cash left with this burn rate they need to raise funds soon.
Now they will generating some revenues for their drug but the market knows with multiple programs all for multiple myeloma apart from one below they will be issuing shares again. So again there is a reason for their roller coaster valuation, multiple platforms probably delayed by pandemic, multiple offering and high cash burn. Their approved PDC for one myeloma is currently their main asset.
Just because their drug has same MOA as TH19 series I don’t think they are right comp for THTX overall operations.
ASCENT
The phase 1/2 ASCENT study is the first study with melflufen outside multiple myeloma. The ASCENT study is an open-label study with melflufen and dexamethasone in patients with AL-amyloidosis, who have undergone at least one previous line of therapy.
https://www.prnewswire.com/news-releases/oncopeptides-publishes-report-for-q1-2021-and-updated-dates-for-the-publication-of-the-reports-for-q2-and-q3-2021-301299546.html
Wino115 wrote: What that valuation informs us on is that one PDC for one indication of mylenoma (and 100% of their pipeline is that same drug for various interations of mylenoma) is worth those market caps you've put up there.
I'm not sure the expected path of earnings from the drug or the peak earnings for it, so don't know what that valuation is supporting as far as a potential revenue number. It may not be far off from what someone would value the option value of TH1902 at this point, and you'd have to add it in to the other THTX assets for a full market cap. But it seems clear if TH1902 shows any evidence of being viable, it should be worth more than melflufin given the wider possible usage and revenue opportunity. Should be multiples of that.
qwerty22 wrote:
You saying offerings explain the Sp? It all looks rational to you with that info?
I guess I have the sense that people pick some "over-achievers" like cydy (lol) to compare THTX to. There are perfectly good companies, executing well, who have much more down to earth valuations. I'm all for balance.
So at IPO 2017 had a valuation of 200 mil euros, about 200 mil USD at the time. It was ready to start it's Ph2 at the time. As I said the stock quickly rose in the following 18 months or so (tripled, more if you include one of your offerings). We are one stage behind that at the moment. With this as a comparator it's reasonable for THTX's to be valued sub 200 mil now with good prospects for growth on good data.
I'm not against the idea the whole THTX package is grossly undervalued.
scarlet1967 wrote:
Since the IPO this company has been diluting their shares just about every year the total proceeds overall were $455 M!! Balanced view please....
Oncopeptides has completed a directed share issue raising approximately SEK 1,106 million (USD 130 million) Regulatory
March 10, 2021
Oncopeptides has completed a directed share issue raising approximately SEK 1,414 million (USD 144 M)
May 6, 2020 - Regulatory press release
Oncopeptides has completed a directed share issue of approximately SEK 727 million (USD 78 M)
June 28, 2019 - Regulatory press release
Oncopeptides has completed a directed share issue of approximately SEK 546 million
January 24, 2019 - Regulatory press release
Oncopeptides has completed a directed share issue of approximately SEK 314 million
March 22, 2018 - Regulatory press release 38